The parenteral nutrition market has grown significantly, and is now worth more than US$ 6 billion by 2021. The industry is expected to reach US$ 7 billion by the end of 2022, representing a 16% increase over 2021. The industry is expected to double in size between 2022 and 2032, reaching US$ 14 billion.
Parenteral nutrition (PN) is a method of delivering nutrients directly into a person’s bloodstream, bypassing the digestive system. This type of nutrition is used when a person is unable to receive adequate nutrition through normal oral or enteral routes, such as through the mouth or through a feeding tube. Parenteral nutrition is usually given through a vein, either in a hospital setting or at home, and is typically used for people with serious medical conditions, such as cancer, pancreatitis, or short bowel syndrome. Parenteral nutrition typically contains a mixture of carbohydrates, proteins, fats, vitamins, and minerals, tailored to meet the specific needs of each individual.
Download Free Sample Copy of this Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=7092
Key Segments Covered in the Parenteral Nutrition Research Report
Prominent parenteral nutrition products manufacturers are striving to continuously improve their product offerings. They do so by introducing new product lines, consolidating their presence through collaborations and acquiring some small to medium-scale providers among others. Some key developments are as follows:
Get Customization on this Report for Specific Research Solutions – https://www.factmr.com/connectus/sample?flag=RC&rep_id=7092
Which Parenteral Nutrient Type is forecast to Remain Dominant?
Single Dose Amino Acid Parenteral Nutrition Solutions to Remain Prominent
By nutrient type, sales of single dose amino acid parenteral nutrition solutions are expected to remain dominant, with an anticipated market share worth 31% in 2022 and beyond. This is attributed to increased usage of amino acid solutions.
Newly procured amino acids possess fewer side effects, thereby enhancing patient benefits. A combination of different amino acid grades have proven to enhance overall biological functioning of the patient. Hence, there is high reliance on this product.
Prospects for Parenteral Lipid Emulsions are expected to Heighten Significantly
Besides single dose amino acids, lipid emulsions are likely to enjoy rapid growth, expanding at a CAGR of 6.7% from 2022 to 2032. Growth is attributed to development of hybrid parenteral lipid emulsions from multiple sources to enhance patient health.
These formulations are manufactured through a combination of fish oil and olive oil. Moreover, the COVID-19 pandemic has prompted healthcare providers to offer parenteral nutrition over enteral approaches, with lipid emulsions proving to be the most convenient option.
For in-depth competitive analysis, Buy Now – https://www.factmr.com/checkout/7092
How do Growth Prospects Appear across the Asia-Pacific Region?
A Large Population Base and the Consequent Nutritional Requirement Bolstering Prospects
Sales of parenteral nutritional products are expected to grow the fastest across the Asia-Pacific. The presence of a large population base and the consequent rise in cases of inadequate nutritional intake- particularly across the developing world- has heightened growth prospects throughout the region.
Countries such as India represent the bulk of all growth opportunities in the long-run. It is reported that every day, more than 6,000 children below the age of 5 succumb to malnutrition in the country. Most of them are a result of lack of vitamin A, iron iodine, zinc and folic acid. About 57% of preschoolers and their mothers have sub-clinical Vitamin A deficiency.
Likewise, in China, mineral insufficiency comprises the highest form of malnutrition among adults, at around 99.97%, followed by vitamin deficiency (98.8%), overweight & obesity (39.58%) and underweight (~4%). Hence, governments are promoting extensive nutritional intake campaigns, elevating growth prospects. Fact.MR expects the Asia-Pacific market to proliferate at a CAGR of 8% through 2032.
US Sales Office:
11140 Rockville Pike
Rockville, MD 20852
Tel: +1 (628) 251-1583
Email: [email protected]